Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Treasury Shares (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Treasury Shares for 4 consecutive years, with $51849.0 as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares fell 95.77% to $51849.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $51849.0, a 95.77% decrease, with the full-year FY2024 number at $44107.0, down 91.85% from a year prior.
  • Treasury Shares was $51849.0 for Q3 2025 at bioAffinity Technologies, down from $1.6 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.6 million in Q1 2025 to a low of $44107.0 in Q4 2024.
  • A 4-year average of $772540.0 and a median of $885218.0 in 2024 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: surged 370.74% in 2023, then tumbled 95.77% in 2025.
  • bioAffinity Technologies' Treasury Shares stood at $114920.0 in 2022, then surged by 370.74% to $540969.0 in 2023, then tumbled by 91.85% to $44107.0 in 2024, then increased by 17.55% to $51849.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Treasury Shares are $51849.0 (Q3 2025), $1.6 million (Q2 2025), and $1.6 million (Q1 2025).